Bristol Myers Squibb Q2 FY26: where the revenue came from and where it went
The whole income statement of Bristol Myers Squibb for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2026
- Reported
- Jul 30, 2026
Revenue$12.97B
+6% year over year
Gross profit$9.25B
71% margin
Operating profit−$0.83B
−6% margin
Net profit$3.32B
26% margin
Net profit is larger than what operations earned, because the statement adds $4.92B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 12.97 | 100% | +6% |
| Growth portfolio | 7.56 | 58% | |
| Eliquis | 4.48 | 35% | |
| Revlimid | 0.43 | 3% | |
| Pomalyst/Imnovid | 0.20 | 2% | |
| Other legacy products | 0.17 | 1% | |
| Sprycel | 0.09 | 1% | |
| Abraxane | 0.06 | 0% | |
| Cost of revenue | −3.73 | 29% | |
| Gross profit | 9.25 | 71% margin | −1pp |
| R&D | −2.96 | 23% | +2pp |
| SG&A | −1.83 | 14% | +0pp |
| Other | −5.29 | 41% | +0pp |
| Operating profit | −0.83 | −6% margin | |
| Other income, net | 4.92 | ||
| Tax | −0.77 | ||
| Net profit | 3.32 | 26% margin | +15pp |
220 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest